Este sitio requiere JavaScript para funcionar apropiadamente. Por favor modifique sus preferencias o utilice un navegador diferente para continuar.


Usted está a punto de salir de la página web de GSK

Este enlace lo llevará a un sitio web que no pertenece a GSK. GSK no recomienda, aprueba ni acepta responsabilidad por los sitios controlados por terceros.



Three patients with COPD, three daily struggles with symptoms

TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with oderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. 1

Discover their stories

Register today

Receive the latest information about TRELEGY Ellipta.


  1. TRELEGY Ellipta Summary of Product Characteristics, 2017.

TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.

© 2017 GlaxoSmithKline Group of Companies. TRELEGY and Ellipta are trademarks of the GSK group of companies.

Materials supplied by the above-country business unit to LOCs, for localisation must be subject to local Medical and/or Regulatory review and approval prior to external distribution